|
176 Companies |
|
232 Products |
|
232 Products |
|
108 Mechanisms of Action |
|
9 Trials |
|
1978 News |
|
| «12345678910111213...4142» |
- ||| guadecitabine (SGI-110) / Otsuka
Trial completion: A Phase II Trial of SGI-110 in Patients With IPSS High and Int 2 Myelodysplastic Syndrome, Acute Myeloid Leukemia With 20-30% Marrow Blasts or Chronic Myelomonocytic Leukemia Type 2 Not Responding to Azacitidine or Decitabine After at Least 6 Courses or Relapsing After a Response (clinicaltrials.gov) - May 4, 2018
P2, N=56, Completed, Sponsor: Groupe Francophone des Myelodysplasies
Active, not recruiting --> Completed
- | daunorubicin / Generic mfg., cytarabine / Generic mfg.
Trial completion date: FAMYLY: Pilot Study Efficacy and Tolerance Fish Oil Emulsion Daunorubicin and Cytarabine Treatment of AML Younger Patients (clinicaltrials.gov) - Apr 27, 2018
P2, N=30, Completed, Sponsor: French Innovative Leukemia Organisation
Active, not recruiting --> Completed Trial completion date: Oct 2016 --> Apr 2018
- Farydak (panobinostat) / Secura Bio
Trial completion date, Combination therapy, Epigenetic controller, Metastases: Phase I Dose Finding and Proof-of-concept Study of Panobinostat With Standard Dose Cytarabine and Daunorubicin for Untreated Acute Myeloid Leukemia or Advanced Myelodysplastic Syndrome (clinicaltrials.gov) - Apr 25, 2018
P1, N=29, Active, not recruiting, Sponsor: University of California, San Francisco
Trial completion date: Oct 2016 --> Apr 2018 Trial completion date: Dec 2017 --> Dec 2018
- |||| Xospata (gilteritinib) / Astellas
Trial completion: Dose Escalation Study Investigating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics of ASP2215 in Patients With Relapsed or Refractory Acute Myeloid Leukemia (clinicaltrials.gov) - Apr 25, 2018
P1/2, N=258, Completed, Sponsor: Astellas Pharma Global Development, Inc.
Trial completion date: Dec 2017 --> Dec 2018 Active, not recruiting --> Completed
- | Trial completion: LAMVIRE: Respiratory Viral Infections During Acute Myeloid Leukemia (AML)Chemotherapy Related Aplasia (clinicaltrials.gov) - Apr 23, 2018
P4, N=119, Completed, Sponsor: Centre Hospitalier Universitaire, Amiens
Active, not recruiting --> Completed Active, not recruiting --> Completed
- | Zarnestra (tipifarnib) / Kura Oncology
Trial completion: Tipifarnib in Treating Patients With Acute Myeloid Leukemia in Remission (clinicaltrials.gov) - Apr 19, 2018
P3, N=144, Completed, Sponsor: National Cancer Institute (NCI)
Active, not recruiting --> Completed Active, not recruiting --> Completed
- | CMD-602 / Cell and Gene Therapy Catapult, Athenex, Baylor College of Medicine
Enrollment open, Gene therapy: WT1 TCR Gene Therapy for Leukaemia: A Phase I/II Safety and Toxicity Study (clinicaltrials.gov) - Apr 19, 2018
P1/2, N=18, Recruiting, Sponsor: Cell Medica Ltd
Active, not recruiting --> Completed Suspended --> Recruiting
- | Phase classification, Trial completion date, Trial primary completion date: Red Cell Transfusion Goals in Patients With Acute Leukemias (clinicaltrials.gov) - Apr 19, 2018
P=N/A, N=90, Active, not recruiting, Sponsor: Sidney Kimmel Comprehensive Cancer Center
Suspended --> Recruiting Phase classification: P1 --> P=N/A | Trial completion date: Jun 2017 --> Dec 2019 | Trial primary completion date: Apr 2017 --> Dec 2018
- | cytarabine / Generic mfg., decitabine / Generic mfg.
Trial completion, Enrollment change, Metastases: Decitabine and Cytarabine in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia, High Risk Myelodysplastic Syndrome, or Myeloproliferative Neoplasm (clinicaltrials.gov) - Apr 13, 2018
P=N/A, N=12, Completed, Sponsor: University of Washington
Phase classification: P1 --> P=N/A | Trial completion date: Jun 2017 --> Dec 2019 | Trial primary completion date: Apr 2017 --> Dec 2018 Active, not recruiting --> Completed | N=30 --> 12
- | Thymoglobulin (anti-thymocyte globulin (rabbit)) / Sanofi
Trial completion date: Phase 2 Haplotype Mismatched HSCT in Patients With Hematological Malignancies (clinicaltrials.gov) - Apr 10, 2018
P2, N=9, Terminated, Sponsor: Sherif S. Farag
Active, not recruiting --> Completed | N=30 --> 12 Trial completion date: May 2016 --> Jul 2017
- | Phase classification, Enrollment change, Trial completion date, Trial primary completion date, Minimal residual disease: Maintenance Therapy With Histamine Dihydrochloride and Interleukin-2 in Adult Acute Myeloid Leukemia (AML) Patients With Measurable Minimal Residual Disease (MRD)- a Non-interventional Study (NIS) (clinicaltrials.gov) - Apr 9, 2018
P, N=8, Terminated, Sponsor: University of Ulm
Trial completion date: May 2016 --> Jul 2017 Phase classification: P=N/A --> P | N=60 --> 8 | Trial completion date: Mar 2016 --> Mar 2018 | Trial primary completion date: Mar 2016 --> Mar 2018
- | Mekinist (trametinib) / Novartis, BeiGene, uprosertib (LAE003) / Laekna Therap
Trial termination, Combination therapy: Trametinib and Akt Inhibitor GSK2141795 in Treating Patients With Acute Myeloid Leukemia (clinicaltrials.gov) - Apr 6, 2018
P2, N=24, Terminated, Sponsor: National Cancer Institute (NCI)
Phase classification: P=N/A --> P | N=60 --> 8 | Trial completion date: Mar 2016 --> Mar 2018 | Trial primary completion date: Mar 2016 --> Mar 2018 Active, not recruiting --> Terminated; Lack of efficacy.
- | Trial completion, Trial completion date, Trial primary completion date: Novel Approaches for Graft-versus-Host Disease Prevention Compared to Contemporary Controls (BMT CTN 1203) (clinicaltrials.gov) - Apr 6, 2018
P2, N=279, Completed, Sponsor: National Heart, Lung, and Blood Institute (NHLBI)
Active, not recruiting --> Terminated; Lack of efficacy. Active, not recruiting --> Completed | Trial completion date: Dec 2018 --> Oct 2017 | Trial primary completion date: Aug 2018 --> Oct 2017
- | Xpovio (selinexor) / Karyopharm
Trial completion, Enrollment change, Trial completion date, Combination therapy: Selinexor and Chemotherapy in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia (clinicaltrials.gov) - Apr 4, 2018
P1, N=23, Completed, Sponsor: Bhavana Bhatnagar
Active, not recruiting --> Completed | Trial completion date: Dec 2018 --> Oct 2017 | Trial primary completion date: Aug 2018 --> Oct 2017 Recruiting --> Completed | N=60 --> 23 | Trial completion date: Dec 2019 --> Mar 2018
- | Enrollment change, Trial completion date, Trial termination, Trial primary completion date: Donor Stem Cell Transplant in Treating Patients With High Risk Acute Myeloid Leukemia (clinicaltrials.gov) - Mar 31, 2018
P1, N=10, Terminated, Sponsor: University of Southern California
Recruiting --> Completed | N=60 --> 23 | Trial completion date: Dec 2019 --> Mar 2018 N=35 --> 10 | Trial completion date: Mar 2019 --> Aug 2017 | Recruiting --> Terminated | Trial primary completion date: Mar 2018 --> Jul 2017; Insufficient Accrual
- | Zolinza (vorinostat) / Merck (MSD)
Trial completion: Phase I/II Study of Combination of Sorafenib, Vorinostat, and Bortezomib for the Treatment of Acute Myeloid Leukemia With Complex- or Poor-risk (Monosomy 5/7) Cytogenetics or FLT3-ITD Positive Genotype (clinicaltrials.gov) - Mar 31, 2018
P1/2, N=37, Completed, Sponsor: Hamid Sayar
N=35 --> 10 | Trial completion date: Mar 2019 --> Aug 2017 | Recruiting --> Terminated | Trial primary completion date: Mar 2018 --> Jul 2017; Insufficient Accrual Recruiting --> Completed
- | Yervoy (ipilimumab) / BMS
Trial completion, Minimal residual disease: Ipilimumab in Treating Patients With Relapsed or Refractory High-Risk Myelodysplastic Syndrome or Acute Myeloid Leukemia (clinicaltrials.gov) - Mar 21, 2018
P1, N=42, Completed, Sponsor: National Cancer Institute (NCI)
Recruiting --> Completed Active, not recruiting --> Completed
- | decitabine / Generic mfg.
Trial completion, Enrollment change: AR-42 and Decitabine in Treating Patients With Acute Myeloid Leukemia (clinicaltrials.gov) - Mar 14, 2018
P1, N=13, Completed, Sponsor: Alison Walker
Active, not recruiting --> Completed Active, not recruiting --> Completed | N=54 --> 13
- | Januvia (sitagliptin) / Merck (MSD)
Trial completion, Trial completion date: Multicenter Phase II of CD26 Using Sitagliptin for Engraftment After UBC Transplant (clinicaltrials.gov) - Mar 14, 2018
P2, N=19, Completed, Sponsor: Sherif S. Farag
Active, not recruiting --> Completed | N=54 --> 13 Active, not recruiting --> Completed | Trial completion date: Nov 2018 --> Dec 2017
- Vyxeos (cytarabine/daunorubicin liposomal formulation) / Jazz, Nippon Shinyaku
Trial withdrawal: Pharmacokinetic and Pharmacodynamic Assessment of Treatment With CPX-351 (Cytarabine: Daunorubicin) Liposome for Injection in Acute Leukemias and MDS Patients With Moderate Hepatic Impairment (clinicaltrials.gov) - Mar 14, 2018
P2, N=0, Withdrawn, Sponsor: Jazz Pharmaceuticals
Active, not recruiting --> Completed | Trial completion date: Nov 2018 --> Dec 2017 Recruiting --> Withdrawn
- | Erwinase (erwinia L-asparaginase) / Jazz, Ohara Pharma
Trial completion, Trial completion date: 1336GCC: Study of Erwinaze for Treatment of Acute Myeloid Leukemia (AML) (clinicaltrials.gov) - Mar 12, 2018
P1, N=5, Completed, Sponsor: Ashkan Emadi
Recruiting --> Withdrawn Active, not recruiting --> Completed | Trial completion date: Dec 2020 --> Sep 2017
- | Simulect (basiliximab) / Novartis
Trial completion, Enrollment change, Trial completion date, IO biomarker: Vaccine Therapy and Basiliximab in Treating Patients With Acute Myeloid Leukemia in Complete Remission (clinicaltrials.gov) - Mar 9, 2018
P1, N=7, Completed, Sponsor: University of Chicago
Active, not recruiting --> Completed | Trial completion date: Dec 2020 --> Sep 2017 Active, not recruiting --> Completed | N=36 --> 7 | Trial completion date: Dec 2017 --> Mar 2018
- || guadecitabine (SGI-110) / Otsuka
Trial completion date: A Phase II Trial of SGI-110 in Patients With IPSS High and Int 2 Myelodysplastic Syndrome, Acute Myeloid Leukemia With 20-30% Marrow Blasts or Chronic Myelomonocytic Leukemia Type 2 Not Responding to Azacitidine or Decitabine After at Least 6 Courses or Relapsing After a Response (clinicaltrials.gov) - Mar 3, 2018
P2, N=56, Active, not recruiting, Sponsor: Groupe Francophone des Myelodysplasies
Active, not recruiting --> Completed | N=36 --> 7 | Trial completion date: Dec 2017 --> Mar 2018 Trial completion date: Feb 2018 --> Apr 2018
- | Mylotarg (gemtuzumab ozogamicin) / UCB, PDL, Pfizer
Phase classification: Gemtuzumab Ozogamicin in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Acute Promyelocytic Leukemia (clinicaltrials.gov) - Mar 2, 2018
P=N/A, N=0, Approved for marketing, Sponsor: Wake Forest University Health Sciences
Trial completion date: Feb 2018 --> Apr 2018 Phase classification: P2 --> P=N/A
- | cyclophosphamide / Generic mfg.
Enrollment change: Allogeneic or Haploidentical Stem Cell Transplant Followed By High-Dose Cyclophosphamide in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia (clinicaltrials.gov) - Mar 1, 2018
P1, N=33, Recruiting, Sponsor: Washington University School of Medicine
Phase classification: P2 --> P=N/A N=75 --> 33
- | Mylotarg (gemtuzumab ozogamicin) / UCB, PDL, Pfizer
Enrollment change, Trial termination, Trial primary completion date: Gemtuzumab Ozogamicin in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Acute Promyelocytic Leukemia (clinicaltrials.gov) - Mar 1, 2018
P2, N=12, Terminated, Sponsor: Wake Forest University Health Sciences
N=75 --> 33 N=30 --> 12 | Suspended --> Terminated | Trial primary completion date: Aug 2020 --> Jul 2016
- | mitoxantrone / Generic mfg., gemcitabine / Generic mfg.
Trial termination: Gemcitabine and Mitoxantrone in Treating Patients With Relapsed Acute Myeloid Leukemia (clinicaltrials.gov) - Feb 22, 2018
P2, N=24, Terminated, Sponsor: The Cleveland Clinic
Completed --> Terminated; If </= 5 of the initial 18 patients had a CR, the study would be stopped. Only 5 patients (21%) of 24 enrolled patients had a CR so the study was terminated.
- cyclophosphamide / Generic mfg., clofarabine / Generic mfg.
Trial termination: POE07-01: Phase I Dose-Escalation Trial of Clofarabine Followed by Escalating Doses of Fractionated Cyclophosphamide in Children With Relapsed or Refractory Acute Leukemias (clinicaltrials.gov) - Feb 15, 2018
P1, N=35, Terminated, Sponsor: Sidney Kimmel Comprehensive Cancer Center
Only 5 patients (21%) of 24 enrolled patients had a CR so the study was terminated. Active, not recruiting --> Terminated; Lack of accrual
- | FLX925 / RAPT Therap
Enrollment change, Trial initiation date, Trial primary completion date: First-in-Human Study of FLX925 in Subjects With Relapsed or Refractory Acute Myeloid Leukemia (clinicaltrials.gov) - Feb 9, 2018
P1, N=51, Terminated, Sponsor: FLX Bio, Inc.
Active, not recruiting --> Terminated; Lack of accrual N=123 --> 51 | Initiation date: Jan 2015 --> Apr 2015 | Trial primary completion date: Mar 2018 --> May 2017
- BI 836858 / Boehringer Ingelheim
Enrollment closed, Enrollment change: BI 836858 Dose Escalation in Patients With Refractory or Relapsed Acute Myeloid Leukemia and in Patients in Complete Remission With High Risk to Relapse (clinicaltrials.gov) - Feb 8, 2018
P1, N=30, Active, not recruiting, Sponsor: Boehringer Ingelheim
N=123 --> 51 | Initiation date: Jan 2015 --> Apr 2015 | Trial primary completion date: Mar 2018 --> May 2017 Recruiting --> Active, not recruiting | N=63 --> 30
- || BI 836858 / Boehringer Ingelheim
Trial completion date, Trial primary completion date: BI 836858 Dose Escalation in Patients With Refractory or Relapsed Acute Myeloid Leukemia and in Patients in Complete Remission With High Risk to Relapse (clinicaltrials.gov) - Feb 6, 2018
P1, N=63, Recruiting, Sponsor: Boehringer Ingelheim
Recruiting --> Active, not recruiting | N=63 --> 30 Trial primary completion date: Mar 2020 --> Apr 2018 | Trial completion date: Mar 2020 --> May 2018
- | Trial completion: Natural History Study of Fungal Infections of the Blood in Patients With Cancer or in Patients Who Have Undergone a Stem Cell Transplant (clinicaltrials.gov) - Feb 1, 2018
P=N/A, N=304, Completed, Sponsor: European Organisation for Research and Treatment of Cancer - EORTC
Trial primary completion date: Mar 2020 --> Apr 2018 | Trial completion date: Mar 2020 --> May 2018 Active, not recruiting --> Completed
- | Enrollment closed, Enrollment change: Ultra-Low Dose IL-2 Therapy as GVHD Prophylaxis in Haploidentical Allogeneic Stem Cell Transplantation (clinicaltrials.gov) - Jan 30, 2018
P1, N=20, Active, not recruiting, Sponsor: National Heart, Lung, and Blood Institute (NHLBI)
Active, not recruiting --> Completed Recruiting --> Active, not recruiting | N=40 --> 20
- | Trial completion: Caregiver Support in the Coping of Patients Who Are Undergoing a Donor Bone Marrow Transplant (clinicaltrials.gov) - Jan 26, 2018
P=N/A, N=36, Completed, Sponsor: The Cleveland Clinic
Recruiting --> Active, not recruiting | N=40 --> 20 Active, not recruiting --> Completed
- | atorvastatin / Generic mfg.
Trial completion, Trial primary completion date: Safety & Efficacy of Atorvastatin for Prophylaxis of Acute Graft Versus Host Disease in Patients With Hematological Malignancies HLA- Donor Hematopoietic Stem Cell Transplantation (clinicaltrials.gov) - Jan 23, 2018
P2, N=40, Completed, Sponsor: Ohio State University Comprehensive Cancer Center
Active, not recruiting --> Completed Active, not recruiting --> Completed | Trial primary completion date: Dec 2016 --> Jan 2014
- | Vyxeos (cytarabine/daunorubicin liposomal formulation) / Jazz, Nippon Shinyaku
Trial completion, Trial primary completion date: A Novel Sequential Treatment of Salvage and Reduced Intensity Conditioning (RIC) Chemotherapy for Allogeneic Stem-Cell Transplantation (SCT) for Primary Refractory and Relapsed Acute Myelogenous Leukemia (AML) (clinicaltrials.gov) - Jan 17, 2018
P1, N=47, Completed, Sponsor: Weill Medical College of Cornell University
Active, not recruiting --> Completed | Trial primary completion date: Dec 2016 --> Jan 2014 Active, not recruiting --> Completed | Trial primary completion date: Dec 2017 --> Jun 2014
- | cyclophosphamide / Generic mfg.
Trial completion, Post-transplantation: Post-transplantation Cyclophosphamide as GVHD Prophylaxis After HSCT (clinicaltrials.gov) - Jan 16, 2018
P2, N=200, Completed, Sponsor: Ivan S Moiseev
Active, not recruiting --> Completed | Trial primary completion date: Dec 2017 --> Jun 2014 Active, not recruiting --> Completed
- | Trial completion, Trial primary completion date: Decitabine Followed by Mitoxantrone Hydrochloride, Etoposide, and Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndromes (clinicaltrials.gov) - Jan 12, 2018
P1/2, N=52, Completed, Sponsor: Fred Hutchinson Cancer Research Center
Active, not recruiting --> Completed Active, not recruiting --> Completed | Trial primary completion date: Dec 2017 --> Aug 2016
- | Trial completion, Trial primary completion date: A Feasibility Study of Prophylactic White Blood Cell Transfusions (clinicaltrials.gov) - Jan 12, 2018
P2, N=45, Completed, Sponsor: M.D. Anderson Cancer Center
Active, not recruiting --> Completed | Trial primary completion date: Dec 2017 --> Aug 2016 Active, not recruiting --> Completed | Trial primary completion date: Sep 2018 --> Nov 2016
- | Trial primary completion date: Lenalidomide and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia (clinicaltrials.gov) - Jan 11, 2018
P1, N=30, Recruiting, Sponsor: Stanford University
Active, not recruiting --> Completed | Trial primary completion date: Sep 2018 --> Nov 2016 Trial primary completion date: Dec 2017 --> Dec 2018
- || Qinprezo (vosaroxin) / Denovo
Phase classification, Trial primary completion date, Combination therapy: Safety and Tolerability Study of Voreloxin and Cytarabine Combination in Acute Myeloid Leukemia in Humans (clinicaltrials.gov) - Jan 9, 2018
P1b/2, N=110, Completed, Sponsor: Sunesis Pharmaceuticals
Trial primary completion date: Dec 2017 --> Dec 2018 Phase classification: P1/2 --> P1b/2 | Trial primary completion date: Jul 2011 --> Feb 2012
- ||| vadastuximab talirine (SGN-CD33A) / Pfizer
Trial completion: A Safety Study of SGN-CD33A in AML Patients (clinicaltrials.gov) - Jan 5, 2018
P1, N=195, Completed, Sponsor: Seattle Genetics, Inc.
Phase classification: P1/2 --> P1b/2 | Trial primary completion date: Jul 2011 --> Feb 2012 Active, not recruiting --> Completed
- lenalidomide / Generic mfg., azacitidine / Generic mfg.
Trial primary completion date: LEN-MEC: Azacitidine + Lenalidomide Combo in the Elderly With Previously Treated AML & High-Risk MDS (clinicaltrials.gov) - Jan 3, 2018
P2, N=33, Terminated, Sponsor: Stanford University
Active, not recruiting --> Completed Trial primary completion date: Aug 2014 --> Mar 2014
- | Thymoglobulin (anti-thymocyte globulin (rabbit)) / Sanofi
Trial termination: Donor Stem Cell Transplant in Treating Patients With Myeloid Cancer or Other Disease (clinicaltrials.gov) - Dec 28, 2017
P2, N=24, Terminated, Sponsor: Masonic Cancer Center, University of Minnesota
Trial primary completion date: Aug 2014 --> Mar 2014 Completed --> Terminated
- | Proleukin (aldesleukin) / Merck (MSD), Novartis, Iovance Biotherap, Thymoglobulin (anti-thymocyte globulin (rabbit)) / Sanofi
Trial completion: Donor Natural Killer Cells and Aldesleukin in Treating Patients w/High Risk AML Undergoing Donor Stem Cell Transplant (clinicaltrials.gov) - Dec 28, 2017
P1/2, N=50, Completed, Sponsor: Masonic Cancer Center, University of Minnesota
Completed --> Terminated Terminated --> Completed
- Vyxeos (cytarabine/daunorubicin liposomal formulation) / Jazz, Nippon Shinyaku
Enrollment closed: A Novel Sequential Treatment of Salvage and Reduced Intensity Conditioning (RIC) Chemotherapy for Allogeneic Stem-Cell Transplantation (SCT) for Primary Refractory and Relapsed Acute Myelogenous Leukemia (AML) (clinicaltrials.gov) - Dec 26, 2017
P1, N=47, Active, not recruiting, Sponsor: Weill Medical College of Cornell University
Terminated --> Completed Terminated --> Active, not recruiting
- | Enrollment closed: Collecting and Storing Malignant, Borderline Malignant Neoplasms, and Related Samples From Young Patients With Cancer (clinicaltrials.gov) - Dec 13, 2017
P=N/A, N=3000, Active, not recruiting, Sponsor: Children's Oncology Group
Terminated --> Active, not recruiting Recruiting --> Active, not recruiting
- | Zolinza (vorinostat) / Merck (MSD)
Trial completion, Trial primary completion date: S1203: Cytarabine and Daunorubicin Hydrochloride or Idarubicin and Cytarabine With or Without Vorinostat in Treating Younger Patients With Previously Untreated Acute Myeloid Leukemia (clinicaltrials.gov) - Dec 8, 2017
P3, N=756, Completed, Sponsor: National Cancer Institute (NCI)
Recruiting --> Active, not recruiting Active, not recruiting --> Completed | Trial primary completion date: Jun 2018 --> Jun 2017
- | Xpovio (selinexor) / Karyopharm
Trial completion, Trial primary completion date, IO biomarker: Decitabine and Selinexor in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia (clinicaltrials.gov) - Dec 8, 2017
P1, N=25, Completed, Sponsor: Bhavana Bhatnagar
Active, not recruiting --> Completed | Trial primary completion date: Jun 2018 --> Jun 2017 Active, not recruiting --> Completed | Trial primary completion date: Jul 2017 --> Nov 2016
- | mitoxantrone / Generic mfg., cytarabine / Generic mfg.
Trial completion: Evaluation of "Dose-dense Therapy" by S-HAM in Comparison to Conventionally Timed Double Induction in Patients With Acute Myeloid Leukemia (AML) (clinicaltrials.gov) - Dec 6, 2017
P3, N=396, Completed, Sponsor: Prof. Dr. Wolfgang Hiddemann
Active, not recruiting --> Completed | Trial primary completion date: Jul 2017 --> Nov 2016 Active, not recruiting --> Completed